Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Rituximab 259Cyclophosphamide 238Etoposide 114Prednisone 97Vincristine 96Doxorubicin 96Peripheral Blood Stem Cell Transplantation 95fludarabine phosphate 87Filgrastim 80Cytarabine 61Lenalidomide 60Mycophenolic Acid 59Melphalan 59Radiotherapy 58Busulfan 52Cyclosporine 50Carmustine 49Whole-Body Irradiation 48Tacrolimus 46Methotrexate 42Antilymphocyte Serum 38Gemcitabine 33Ifosfamide 32Carboplatin 32fludarabine 31Dexamethasone 31polatuzumab vedotin 29Granulocyte Colony-Stimulating Factor 29CT-P10 28Methylprednisolone 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large B-Cell, Diffuse × tislelizumab × Clear all
NCT05659628 2022-12-21

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Ningbo No. 1 Hospital

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡